- Trials with a EudraCT protocol (10,507)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10,507 result(s) found for: Blood Disease.
Displaying page 94 of 526.
EudraCT Number: 2007-004761-17 | Sponsor Protocol Number: SG033-0003 | Start Date*: 2008-05-14 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previo... | |||||||||||||
Medical condition: acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) AT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003101-53 | Sponsor Protocol Number: ARTinMMS | Start Date*: 2007-01-10 | |||||||||||
Sponsor Name:Karolinska Institutet | |||||||||||||
Full Title: A randomised placebo controlled study of transdermal testosterone therapy (testosterone 1% hydroalcohol gel) to investigate the efficacy and safety in men with abdominal obesity, low testosterone l... | |||||||||||||
Medical condition: The metabolic syndrome constitutes a cluster of risk factors for cardiovascular disease with increased morbidity and mortality. The metabolic syndrome is referred to as a concomitant occurrence of ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004746-10 | Sponsor Protocol Number: NTA1702 | Start Date*: 2021-01-27 | |||||||||||||||||||||||||||||||
Sponsor Name:The Florey Institute of Neuroscience and Mental Health | |||||||||||||||||||||||||||||||||
Full Title: STOP-MSU – Stopping haemorrhage with Tranexamic acid for hyperacute Onset Presentation including Mobile Stroke Units | |||||||||||||||||||||||||||||||||
Medical condition: Intracerebral Haemorrhage | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003888-22 | Sponsor Protocol Number: MEF-HF-2020-01 | Start Date*: 2020-11-17 |
Sponsor Name:University of Zagreb School of Medicine | ||
Full Title: A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients | ||
Medical condition: Heart failure Heart failure with reduced ejection fraction Advanced Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HR (Ongoing) NL (Ongoing) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001205-16 | Sponsor Protocol Number: 54767414SMM3001 | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003767-25 | Sponsor Protocol Number: APL2-C3G-310 | Start Date*: 2022-03-08 | |||||||||||||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolif... | |||||||||||||||||||||||
Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) CZ (Completed) BE (Completed) AT (Trial now transitioned) FR (Completed) PL (Completed) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005259-18 | Sponsor Protocol Number: PROUD-PV | Start Date*: 2013-08-15 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera | |||||||||||||
Medical condition: Polycythemia Vera | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001524-30 | Sponsor Protocol Number: 20140128 | Start Date*: 2014-12-11 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab | |||||||||||||
Medical condition: Hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) IT (Completed) BE (Completed) DE (Completed) IS (Completed) GB (Completed) ES (Prematurely Ended) CZ (Completed) IE (Prematurely Ended) NL (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007105-36 | Sponsor Protocol Number: Droxidopa-304 | Start Date*: 2009-06-03 |
Sponsor Name:Chelsea Therapeutics Inc. | ||
Full Title: A Multi-Centre, One Year Open-Label Study to Assess the Long-Term Safety of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-003272-31 | Sponsor Protocol Number: NL.EPITRAC.0107.17 | Start Date*: 2018-05-18 | ||||||||||||||||
Sponsor Name:St. Antonius Ziekenhuis | ||||||||||||||||||
Full Title: Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia | ||||||||||||||||||
Medical condition: Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012394-35 | Sponsor Protocol Number: CCAD106A2203 | Start Date*: 2010-03-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer’s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon... | |||||||||||||
Medical condition: Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002984-24 | Sponsor Protocol Number: PHS-Px-104-II-01 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:Phenex Pharmaceuticals AG | |||||||||||||
Full Title: A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients | |||||||||||||
Medical condition: Non-alcoholic fatty liver disease (NAFLD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003489-41 | Sponsor Protocol Number: CADPT03A12101 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:NOVARTIS PHARMA AG | |||||||||||||
Full Title: A first-in-patient Phase I/II clinical study to investigate the safety and efficacy of genome-edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell dis... | |||||||||||||
Medical condition: Sickle Cell Disease (SCD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004877-38 | Sponsor Protocol Number: PREVENT-MINS | Start Date*: 2021-06-18 | |||||||||||
Sponsor Name:Uniwersytet Jagielloński - Collegium Medicum | |||||||||||||
Full Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial | |||||||||||||
Medical condition: Myocardial Injury after Noncardiac Surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003984-12 | Sponsor Protocol Number: TP0001 | Start Date*: 2016-02-05 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) BE (Completed) PL (Completed) LT (Prematurely Ended) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000153-31 | Sponsor Protocol Number: AIR001-CS06 | Start Date*: 2013-01-22 |
Sponsor Name:Aires Pharmaceuticals, Inc | ||
Full Title: A Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension | ||
Medical condition: Pulmonary Arterial Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-002136-40 | Sponsor Protocol Number: 261203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 y... | |||||||||||||
Medical condition: Severe hemophilia A (FVIII <1%) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) AT (Completed) HU (Completed) DE (Completed) NL (Prematurely Ended) BE (Completed) NO (Completed) DK (Completed) FI (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001976-75 | Sponsor Protocol Number: 20130385 | Start Date*: 2014-09-11 | ||||||||||||||||
Sponsor Name:Amgen Inc | ||||||||||||||||||
Full Title: A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Back... | ||||||||||||||||||
Medical condition: Dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) GR (Completed) IT (Completed) FI (Completed) EE (Completed) SK (Completed) LV (Completed) DE (Completed) LT (Completed) CZ (Completed) PT (Completed) BE (Completed) HU (Completed) DK (Completed) ES (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010067-16 | Sponsor Protocol Number: CN156018 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ... | |||||||||||||
Medical condition: ALZHEIMER DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006274-29 | Sponsor Protocol Number: ZEMPLAR | Start Date*: 2009-11-18 | ||||||||||||||||
Sponsor Name:Karolinska Institutet at Danderyd University Hospital | ||||||||||||||||||
Full Title: Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation | ||||||||||||||||||
Medical condition: Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26) Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
